Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2021

View Archived Issues

Hongyun Biotech identifies new EGFR inhibitors

New ATR kinase inhibitors discovered at Shenzhen Life Fountain Biotech

Researchers unveil ACOT13, PTGER2 as candidate genes of autosomal dominant polycystic kidney disease

GTPase KRAS mutant inhibitors patented by Genfleet Therapeutics

Biopolar Hongye presents new Janus kinase inhibitors

JAK inhibitors divulged by Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical

CLIP-170S confers resistance to taxane-based therapy in gastric cancer

IpY.20 targets p27Kip1 to evade breast cancer resistance driven by CDK4 and CDK2

MCC-1734 inhibits cancer cells with different resistance mechanisms

Mouse model of metaplastic breast cancer with conditional overexpression of TRIM24

Novel XO inhibitors show efficacy in acute hyperuricemia rat model

P38 targeting reverses immunosuppressive tumor microenvironment in metastatic breast cancer

FibroGen exercises license option for HiFiBiO's anti-CCR8 monoclonal antibody program

IFI27 as a potential new gene biomarker for severe COVID-19

Aridis' AR-701 is broadly reactive against Omicron and other SARS-CoV-2 variants

RaQualia and Hisamitsu to enter license agreement for sodium channel blocker

Choline transporter in fruit fly brain tunes out unnecessary information

Extension of Series A financing at Ambys supports progression of AMI-918 for liver disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...